Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) Sees Significant Decrease in Short Interest

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) was the target of a significant drop in short interest in June. As of June 30th, there was short interest totaling 3,709 shares, a drop of 77.6% from the June 15th total of 16,531 shares. Based on an average daily volume of 53,981 shares, the short-interest ratio is presently 0.1 days.

Rocket Pharmaceuticals Stock Performance

RCKTW stock remained flat at $0.00 during midday trading on Monday. 4,543 shares of the company’s stock traded hands, compared to its average volume of 30,642. The business has a fifty day moving average price of $0.01 and a two-hundred day moving average price of $0.01. Rocket Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.08.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.

Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW.